Ann and Robert H. Lurie Children's Hospital: FDA Approves New Breakthrough Therapy for Cystic Fibrosis
October 23, 2019
October 23, 2019
CHICAGO, Illinois, Oct. 23 -- The Ann and Robert H. Lurie Children's Hospital issued the following news release:
* * *
- Treatment approved for approximately 90 percent of patients with cystic fibrosis, many of whom had no approved therapeutic options
* * *
The U.S. Food and Drug Administration today approved Trikafta (elexacaftor/ivacaftor/tezacaftor), the first triple combination therapy available to treat patients with the most common cystic . . .
* * *
- Treatment approved for approximately 90 percent of patients with cystic fibrosis, many of whom had no approved therapeutic options
* * *
The U.S. Food and Drug Administration today approved Trikafta (elexacaftor/ivacaftor/tezacaftor), the first triple combination therapy available to treat patients with the most common cystic . . .